BioSpace News Archive

Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim’s position in the cancer vaccine and T-cell engager spaces

Paper published in Journal of Biological Chemistry demonstrates compatibility with downstream manufacturing technologies to help accelerate CAR-T or antibody therapeutics development

Luminex Corporation announced 4th quarter 2020 revenue of approximately $111M, up approximately 23% over the 4th quarter of 2019 and full-year revenue of approximately $417M, up approximately 25% over the full year 2019.

Opticyte Secures $4.6 Million in Funding to Develop First Cell O 2 Monitor for Reducing Organ Failure Opticyte obtains funding from a $2.9MM SBIR Phase IIB grant and completes a $1.7MM seed round to launch first observational trial of Opticyte Cell O 2 Monitor

Effective January 4, 2021, North American Partners in Anesthesia will deliver anesthesia services to the Piedmont Orthopedics | OrthoAtlanta ambulatory surgery center in Fayetteville, Georgia.

Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today highlights recent achievements and outlines expected key 2021 milestones at the J.P. Morgan 39 th Annual Healthcare Conference, held virtually. “2020 was a foundational year for A

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, pre-announces preliminary unaudited fourth quarter 2020 and full-year 2020 results ahead of filing its Form 10-K.

MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Approval of the PMA Supplement for the WEB 17 System, a new addition to the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced the completion of patient enrollment in the LIFT study, a Phase 2a NASH clinical trial of TERN-101,

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it and certain of its wholly owned subsidiaries (collectively, La Jolla) have entered into an exclusive licensing agreement with PAION AG and its wholly owned subsidiary (PAION) for GIAPREZA™